Lead Product(s) : Icodextrin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DSR 2.0 therapy involves the use of the peritoneal cavity for the removal of sodium via diffusion. The body responds by eliminating the associated fluid via osmotic ultrafiltration or urination. It is being investigated for congestive heart failure.
Product Name : DSR 2.0
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 03, 2023
Lead Product(s) : Icodextrin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Berenberg
Deal Size : $16.3 million
Deal Type : Private Placement
Details : Hyloris currently envisages using the net proceeds of the offering to primarily fund the development of additional new product candidates including HY-073 and accelerate in-house R&D activities, including repurposing and analytical expertise.
Product Name : HY-073
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 31, 2022
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Berenberg
Deal Size : $16.3 million
Deal Type : Private Placement
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Berenberg
Deal Size : $16.2 million
Deal Type : Private Placement
Details : Hyloris will use the net proceeds of the Offering primarily to fund the development of new products and accelerate in-house R&D activities including HY-073 (IV acetylsalicylic acid).
Product Name : HY-073
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 04, 2022
Lead Product(s) : Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Berenberg
Deal Size : $16.2 million
Deal Type : Private Placement